SARASOTA, FL -- (MARKET WIRE) -- April 04, 2007 -- DNAPrint™ Genomics, Inc. (OTCBB: DNAG) today reported that several advancements in its proprietary DNA research on PT-401 and Statinome formed the basis for three papers that were presented by DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., and Neil Kabrun, Ph.D., a senior scientist with the DNAPrint Computational Biology Group, at the recent annual meeting of the American Society for Clinical Pharmacology and Therapeutics held in Anaheim, Calif.
